Skip to content
ClinCalc Pro
Menu
Fluoroquinolone Antibiotic Pregnancy: Available data on administration to pregnant women indicate no malformative or feto/neonatal toxicity, but because effects on immature cartilage have been observed with quinolones in juvenile and prenatal animals, damage to articular cartilage in the human immature organism/foetus cannot be excluded. As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy. Ciprofloxacin is excreted in breast milk and, due to the potential risk of articular damage, should not be used during breast-feeding.

Ciprofloxacin (UTI/Prostatitis)

Brand names: Ciproxin

Ciprofloxacin is an oral and intravenous fluoroquinolone antibiotic; here it is used for complicated UTI and acute or chronic bacterial prostatitis owing to its good prostatic and urinary tissue penetration. Its use is now restricted to situations where other antibiotics are unsuitable.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Urinary tract infections — uncomplicated cystitis: 250 mg twice daily to 500 mg twice daily. Complicated cystitis or uncomplicated pyelonephritis: 500 mg twice daily. Complicated pyelonephritis: 500 mg twice daily to 750 mg twice daily. Prostatitis: 500 mg twice daily to 750 mg twice daily.
Route: Oral — tablets swallowed unchewed with fluid; can be taken independently of mealtimes (absorption is more rapid on an empty stomach)
Frequency: Twice daily
Durations from the SPC table: uncomplicated cystitis 3 days (in pre-menopausal women, a 500 mg single dose may be used); complicated cystitis / uncomplicated pyelonephritis 7 days; complicated pyelonephritis at least 10 days, and can be continued for longer than 21 days in some specific circumstances (such as abscesses); prostatitis 2 to 4 weeks (acute) to 4 to 6 weeks (chronic). Other genito-urinary regimens in the same table: gonococcal urethritis and cervicitis 500 mg as a single dose (1 day); epididymo-orchitis and pelvic inflammatory disease 500 mg twice daily to 750 mg twice daily for at least 14 days. The SPC states the dosage is determined by the indication, the severity and site of infection, the susceptibility of the causative organism, the renal function of the patient and, in children and adolescents, body weight. The highest adult oral regimen appearing in the SPC table is 750 mg twice daily; no explicit adult maximum daily dose is stated in the retrieved text, so maxDose is omitted. In patients with impaired liver function no dose adjustment is required. In severe cases, or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible. Section 4.4 (special warnings) and section 4.8 (undesirable effects) were both cut off at the source-fetch limit in this bundle, and no section 4.5 (interactions) text was captured — the interaction entries below are taken from section 4.3 and from the method-of-administration paragraph in section 4.2, which cross-reference section 4.5. Clinician to verify the complete SPC before publication. The paediatric complicated UTI / pyelonephritis regimen is held in paedDose.

Paediatric dose

Route: Oral
Frequency: Twice daily
Max: 750 mg per dose
Paediatric population, complicated urinary tract infections and pyelonephritis (SPC section 4.2 table): 10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily, with a maximum of 750 mg per dose, total duration 10 to 21 days. The SPC gives a range rather than a single per-kg figure, so dosePerKg is left null — the exact quoted range is 10 mg/kg to 20 mg/kg twice daily. Other paediatric regimens in the same table: cystic fibrosis 20 mg/kg twice daily (max 750 mg per dose) for 10 to 14 days; inhalation anthrax post-exposure prophylaxis 10 mg/kg to 15 mg/kg twice daily (max 500 mg per dose) for 60 days; other severe infections 20 mg/kg twice daily (max 750 mg per dose). Dosing in children with impaired renal and/or hepatic function has not been studied. Verify any under-18 use against a children's formulary.

Dose adjustments

Renal

Recommended starting and maintenance oral doses in impaired renal function (SPC section 4.2 table): creatinine clearance greater than 60 mL/min/1.73 m² (serum creatinine less than 124 micromol/L) — usual dosage; creatinine clearance 30 to 60 mL/min/1.73 m² (serum creatinine 124 to 168 micromol/L) — 250 to 500 mg every 12 hours; creatinine clearance less than 30 mL/min/1.73 m² (serum creatinine greater than 169 micromol/L) — 250 to 500 mg every 24 hours; patients on haemodialysis — 250 to 500 mg every 24 hours (after dialysis); patients on peritoneal dialysis — 250 to 500 mg every 24 hours. Elderly patients should receive a dose selected according to the severity of the infection and the patient's creatinine clearance.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance, to other quinolones or to any of the excipients
  • Concomitant administration of ciprofloxacin and tizanidine

Side effects

  • Nausea and diarrhoea — the most commonly reported adverse drug reactions
  • Vomiting, gastrointestinal and abdominal pains, dyspepsia (uncommon)
  • Headache, dizziness, sleep disorders, taste disorders (uncommon)
  • Increase in transaminases, increased bilirubin (uncommon); rash and pruritus (skin section truncated in the fetched text)
  • Eosinophilia and mycotic superinfections (uncommon)
  • Ventricular arrhythmia, torsades de pointes and ECG QT prolongation (frequency not known; reported predominantly in patients with risk factors for QT prolongation)

Interactions

  • Tizanidine — concomitant administration is contraindicated (SPC section 4.3, cross-referencing section 4.5)
  • Dairy products (e.g. milk, yoghurt) and mineral-fortified fruit juice (e.g. calcium-fortified orange juice) — ciprofloxacin tablets should not be taken with these (SPC section 4.2 method of administration, cross-referencing section 4.5)
  • Note: the section 4.5 interactions text itself was not captured in this source bundle — the full list must be checked against the SPC

Clinical monograph

How it works

It inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and causing bacterial death, with broad Gram-negative activity including many uropathogens.

Prescribing in practice

  • Following MHRA warnings, reserve fluoroquinolones for when alternatives cannot be used, and stop at the first sign of tendon pain, neuropathy, or serious psychiatric reactions because some effects can be long-lasting or irreversible.
  • It prolongs the QT interval and interacts with multivalent cation antacids, dairy, and other agents that reduce its absorption or compound toxicity.
  • Avoid concurrent NSAIDs where possible and use caution in those at risk of aortic aneurysm or seizures per the SPC.

Monitoring

Monitor for tendon, neurological, and psychiatric adverse effects clinically and review blood glucose in those at risk of dysglycaemia.

Counselling the patient

  • Stop and seek advice immediately if you develop tendon pain or swelling, pins and needles, or marked mood changes.
  • Separate doses from indigestion remedies, dairy, and iron or calcium supplements.
  • Avoid excessive sun exposure as the skin may become more sensitive.

Evidence & guidelines

Long-established efficacy in complicated UTI and bacterial prostatitis, with its place in therapy now constrained by regulatory safety reviews.

Reference: MHRA Drug Safety Update 2019; NICE NG112; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.